The bookends are in place and the countdown to top-line has begun. 5 scientific meetings (Vascular Discovery, EAS, GRC, ADA, ERA-EDTA) over the next 8 weeks, with ERA-EDTA being at the tail end of that range June 13-16 (including a Resverlogix sponsored symposium at ERA-EDTA). Plus throw in BIO International in early June. Very unlikely (not impossible) to have top-line data before these above events conclude. However, a great opportunity to promote apabetalone, BETonMACE and Resverlogix at cardio, diabetes, renal, and epigenetics meetings, as well as an investor conference, in advance of top-line. 

Ladies and gentlemen, it's going to be a wild ride if top-line data is positive. 135 days to ESC 2019, where I predict full data presentation of the primary MACE outcome by Dr. Kausik Ray and colleagues. Then the following 3 months after ESC could be very exciting with 2 Alzheimer's meetings (CTAD and CTAD Asia), cardio meeting (AHA), kidney meeting (ASN), diabetes meeting (EASD) giving meeting opportunities to present secondary and exploratory analysis full data as well as pre-specified subgroup analyses of the primary outcome (see here for summary). Plus, expect scientific publication of clinical trial data in high impact factor (that's for you Fenix) journal(s), especially if the data is positive.

European Society of Cardiology (ESC) August 31 to Sept 4, 2019; Paris, France

Clinical Trials on Alzheimer's Disease/Asia  (CTAD Asia) September 13-14, 2019; Beijing, China

European Association for the Study of Diabetes (EASD): Sept 16-20, 2019; Barcelona, Spain

American Society for Nephrology (ASN) Kidney Week Nov 5-10, 2019; Washington, D.C.

American Heart Association (AHA) November 16-18, 2019; Philadelphia, PA

Clinical Trials on Alzheimer's Disease (CTAD) December 4-7, 2019; San Diego, CA

Good luck to all!

BearDownAZ